Uveitis Treatment Market to Reach $1.4 Billion by 2034 with 7% CAGR, Says Fact.MR

The global market for uveitis treatment is projected to reach a valuation of $791 million in 2024 and is expected to grow at a compound annual growth rate (CAGR) of 5.8% from 2024 to 2034, as outlined in a recent report by Fact.MR. Technological advancements, particularly in sustained-release drug delivery devices, are pivotal in driving this market expansion.

New treatment methods, including biodegradable microspheres and intravitreal implants, provide significant benefits. These methods offer direct and prolonged pharmaceutical exposure to the affected eye tissues, thereby reducing the need for repeated injections or systemic medications. This not only lowers the risk of undesirable systemic effects but also increases patient compliance and convenience.

Several factors are contributing to the rising incidence of uveitis, such as the increasing aging population in some countries and the growing prevalence of autoimmune disorders. Additionally, there is an emphasis on improving diagnostic capabilities. Increased funding from pharmaceutical companies and organizations for research and development initiatives aimed at uveitis treatment is driving the exploration of new medicinal agents and treatment strategies.

Key insights from the market study indicate that the global market for uveitis treatment is expected to reach $1.4 billion by the end of 2034. North America is set to hold 36.8% of the global market share in 2024, while demand in East Asia is projected to reach a market value of $117 million in the same year. The Canadian market is expected to generate revenue of $90 million by 2034, and South Korea’s market is forecasted to expand at a CAGR of 9.4% from 2024 to 2034. The anterior uveitis segment is predicted to hold 59.5% of the global market share by 2034. In North America, the United States is expected to dominate the market with a 73.4% revenue share in 2024.

A Fact.MR analyst noted that the revenue from uveitis treatment is growing steadily due to advancements such as sustained-release medication delivery techniques, which improve patient convenience and therapeutic efficacy.

Several leading players are driving innovation in the uveitis treatment market. Key players include Sun Pharmaceutical Industries Ltd., EyePoint Pharmaceuticals, Inc., Ophthotech Corporation, Regeneron Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Inflammasome Therapeutics Inc., Graybug Vision, Inc., TopiVert Pharma Ltd., Pfizer Inc., and Bausch Health Companies Inc.

Hospital pharmacies play a crucial role in the distribution of uveitis medications, generating substantial revenue compared to other distribution channels such as retail pharmacies, online pharmacies, and drug stores. Hospitals face a constant need for uveitis medications due to the condition’s prevalence and the ongoing care it requires. Additionally, hospitals benefit financially from treating an increasing number of uveitis patients who need continuous access to prescribed medications. Hospital pharmacies often secure discounted rates on medications due to contracts with specific suppliers.

In industry news, Tarsier Pharma received FDA permission in January 2024 for the Tarsier-04 Phase 3 trial of the TRS01 ocular solution under the Special Protocol Assessment (SPA). The FDA approved triamcinolone acetonide injectable suspension, or XIPER, in October 2021 for use as a suprachoroidal medication to treat retinal edema associated with uveitis. In December 2020, Alimera Sciences Europe Ltd. launched ILUVIEN in the Netherlands to expand its reach for treating non-infectious posterior segment uveitis (NIPU) and diabetic macular edema (DME).

The market analysis from 2019 to 2023 and the forecast from 2024 to 2034 cover various treatment methods, diseases, causes, and distribution channels across major regions globally. Key treatments include corticosteroids, immunosuppressants, monoclonal antibodies, cycloplegic agents, antibiotics, antivirals, antifungals, and analgesics. The diseases covered include anterior uveitis, posterior uveitis, intermediate uveitis, and panuveitis. The causes include infectious and non-infectious uveitis, and the distribution channels reviewed are hospital pharmacies, retail pharmacies, online pharmacies, and drug stores.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!